Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Gold Trust (IAU) vs Organon & Co. Common Stock (OGN) Price & Performance

iShares Gold TrustTrade
Organon & Co. Common StockTrade

Price performance (Past 24H)

Key statistics

iShares Gold Trust vs Organon & Co. Common Stock — how do they compare? iShares Gold Trust trades at $77.8 (market cap $62.13B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares Gold Trust is far larger — about 17.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 51 Days and Organon & Co. Common Stock for 0 Days on average.

IAUOGN
Market Cap
$62.13B$3.62B
Volume
3,713,0952,892,999
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$101.57$13.81
52-Week Low
$74.21$5.70
Typical Hold Time
51 Days0 Days
Enterprise Value
—$11.04B
Dividend Yield
—0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Gold Trust

IAU shares are trading at $78.25, down 0.11% with bearish technical signals dominating the short-term outlook. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has provided some support. Technical indicators show selling pressure outweighing buying signals, with moving averages pointing downward and key resistance at $79.

The stock faces headwinds from monetary policy uncertainty and yield pressures, but potential exists if inflation concerns resurface. Key risks include continued rate hike expectations and dollar strength, while opportunities may emerge from safe-haven demand during market volatility. The technical setup suggests caution in the near term with support at $78.

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IAU
53% Buy47% Sell
Avg holding period · 51 Days
OGN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About iShares Gold Trust

IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.

Read more on IAU →

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →